# Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

> **NCT03154827** · PHASE1,PHASE2 · TERMINATED · sponsor: **BioLineRx, Ltd.** · enrollment: 1 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** BL-8040
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03154827
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-08
- **Primary completion:** 2020-04-01
- **Final completion:** 2020-04-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to lack of enrollment
- **Last updated:** 2024-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03154827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03154827, "Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03154827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*